[go: up one dir, main page]

PE20090326A1 - Compuestos heterociclos como inhibidores de erk - Google Patents

Compuestos heterociclos como inhibidores de erk

Info

Publication number
PE20090326A1
PE20090326A1 PE2008000942A PE2008000942A PE20090326A1 PE 20090326 A1 PE20090326 A1 PE 20090326A1 PE 2008000942 A PE2008000942 A PE 2008000942A PE 2008000942 A PE2008000942 A PE 2008000942A PE 20090326 A1 PE20090326 A1 PE 20090326A1
Authority
PE
Peru
Prior art keywords
alkyl
compounds
formula
erk inhibitors
alkenyl
Prior art date
Application number
PE2008000942A
Other languages
English (en)
Inventor
Alan Cooper
Yongqi Deng
Jr Gerald W Shipps
Neng-Yang Shih
Hugh Zhu
Joseph Kelly
Ronald Doll
Yang Nan
Jagdish Desai
James Wang
Sunil Paliwal
Hon-Chung Tsui
Sobhana Babbu Boga
Abdul-Basit Alhassan
Xiaolei Gao
Liang Zhu
Mehul Patel
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/810,282 external-priority patent/US8546404B2/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20090326A1 publication Critical patent/PE20090326A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A COMPUESTOS HETEROCICLOS DE FORMULA (1.0) DONDE Y1, Y2 E Y3 SON CADA UNO -CH=, -N= O -CR9=, EN DONDE R9 ES HALOGENO, CN, NO2, ENTRE OTROS; z ES DE 1 A 3; Q ES UN COMPUESTO DE FORMULA (2.1), (2.6), ENTRE OTROS, DONDE R3, R4, R5, R6 Y R7 SON CADA UNO H, ALQUENILO(C2-C15), ALQUILO(C1-C20), CICLOALQUILO(C3-C7), ENTRE OTROS; R1 ES CN, NO2, CF3, ALQUENILO(C2-C15), ENTRE OTROS; R2 ES H, CN, HALO, ALQUILO(C1-C20), ENTRE OTROS; R8 ES H, OH, ALQUILO(C1-C20), ENTRE OTROS; R35 ES H O ALQUILO(C1-C6); R36 ES H, ALQUILO(C1-C20) U O-ALQUILO(C1-C20). SON COMPUESTOS PREFERIDOS LOS COMPUESTOS DE FORMULA (i), (ii), ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ACTIVIDAD DE ERK1 Y ERK2 SIENDO UTILES EN EL TRATAMIENTO DE CANCER DE PULMON, LEUCEMIAS MIELOIDES, MELANOMA, SARCOMA
PE2008000942A 2007-06-05 2008-06-04 Compuestos heterociclos como inhibidores de erk PE20090326A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/810,282 US8546404B2 (en) 2005-12-13 2007-06-05 Compounds that are ERK inhibitors

Publications (1)

Publication Number Publication Date
PE20090326A1 true PE20090326A1 (es) 2009-04-04

Family

ID=39737670

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000942A PE20090326A1 (es) 2007-06-05 2008-06-04 Compuestos heterociclos como inhibidores de erk

Country Status (20)

Country Link
EP (1) EP2155722B1 (es)
JP (1) JP2010529122A (es)
KR (1) KR20100025553A (es)
CN (1) CN101815711A (es)
AR (1) AR068046A1 (es)
AU (1) AU2008262412A1 (es)
BR (1) BRPI0812450A2 (es)
CA (1) CA2694860A1 (es)
CL (1) CL2008001633A1 (es)
CO (1) CO6251261A2 (es)
EC (1) ECSP099781A (es)
IL (1) IL202317A0 (es)
MX (1) MX2009013333A (es)
MY (1) MY148609A (es)
NZ (1) NZ581698A (es)
PE (1) PE20090326A1 (es)
RU (1) RU2475484C2 (es)
TW (1) TW200911262A (es)
WO (1) WO2008153858A1 (es)
ZA (1) ZA200908477B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
WO2009105500A1 (en) * 2008-02-21 2009-08-27 Schering Corporation Compounds that are erk inhibitors
WO2010021978A2 (en) * 2008-08-19 2010-02-25 Schering Corporation Il-8 biomarker
US9229008B2 (en) 2008-08-19 2016-01-05 Merck Sharp & Dohme Corp. IL-8 level as a determinant of responsivity of a cancer to treatment
AR078411A1 (es) 2009-05-07 2011-11-09 Lilly Co Eli Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
WO2012015932A2 (en) * 2010-07-27 2012-02-02 Protexer, Inc. Shoe cover removal apparatus
EP2613782B1 (en) * 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
CN103450163B (zh) * 2012-05-29 2017-06-23 中国医学科学院药物研究所 吲唑类化合物、其制备方法及其药物用途
WO2014026327A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
WO2014026329A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
IN2015DN01328A (es) 2012-09-19 2015-07-03 Novartis Ag
KR20160081908A (ko) 2013-10-03 2016-07-08 쿠라 온콜로지, 인크. Erk의 억제제 및 사용 방법
CA2922532C (en) 2013-11-01 2023-09-19 Novartis Ag Aminoheteroaryl benzamides as kinase inhibitors
AU2014368927B2 (en) * 2013-12-20 2018-10-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of CDK and ERK inhibitors
JP2017502016A (ja) * 2013-12-20 2017-01-19 バイオメッド バレー ディスカバリーズ，インコーポレイティド １型ｍｅｋ阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがんの処置
EP4389225A3 (en) * 2013-12-20 2024-10-09 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of type 2 mek and erk inhibitors
WO2015095819A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of erk and raf inhibitors
WO2016095088A1 (en) * 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
WO2016095089A1 (en) * 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
EP3256450B1 (en) 2015-02-11 2020-12-02 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
RU2018117503A (ru) 2015-10-27 2019-11-28 Мерк Шарп И Доум Корп. ЗАМЕЩЕННЫЕ ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORγТ И ИХ ПРИМЕНЕНИЕ
EP3368535B1 (en) 2015-10-27 2020-12-02 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
AU2016344111A1 (en) 2015-10-27 2018-05-10 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
CA3090842A1 (en) 2018-03-12 2019-09-19 Abbvie Inc. Inhibitors of tyrosine kinase 2 mediated signaling
EP3725777A1 (en) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- and pyrido-pyrazoles as protein kinase inhibitors
CN114605329B (zh) * 2022-03-28 2024-01-26 河南中医药大学 取代的吲唑甲酰胺或取代的氮杂吲唑甲酰胺类flt3抑制剂及其用途
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US6632455B2 (en) 1997-12-22 2003-10-14 Schering Corporation Molecular dispersion composition with enhanced bioavailability
US6130235A (en) * 1998-05-22 2000-10-10 Scios Inc. Compounds and methods to treat cardiac failure and other disorders
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
US6706711B2 (en) * 2001-04-27 2004-03-16 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitor
TW200607803A (en) * 2004-05-14 2006-03-01 Vertex Pharma Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto
AU2006326616B2 (en) * 2005-12-13 2012-09-06 Merck Sharp & Dohme Llc Polycyclic indazole derivatives that are ERK inhibitors

Also Published As

Publication number Publication date
ZA200908477B (en) 2012-05-30
JP2010529122A (ja) 2010-08-26
IL202317A0 (en) 2010-06-30
ECSP099781A (es) 2010-01-29
AU2008262412A2 (en) 2010-01-07
CA2694860A1 (en) 2008-12-18
WO2008153858A1 (en) 2008-12-18
BRPI0812450A2 (pt) 2019-09-24
EP2155722B1 (en) 2013-08-14
RU2475484C2 (ru) 2013-02-20
CN101815711A (zh) 2010-08-25
EP2155722A1 (en) 2010-02-24
CO6251261A2 (es) 2011-02-21
CL2008001633A1 (es) 2008-12-12
MY148609A (en) 2013-05-15
NZ581698A (en) 2012-09-28
AR068046A1 (es) 2009-11-04
AU2008262412A1 (en) 2008-12-18
RU2009148867A (ru) 2011-07-20
TW200911262A (en) 2009-03-16
KR20100025553A (ko) 2010-03-09
MX2009013333A (es) 2010-01-18

Similar Documents

Publication Publication Date Title
PE20090326A1 (es) Compuestos heterociclos como inhibidores de erk
PE20100562A1 (es) Derivados policiclicos de indazol como inhibidores de erk
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20091400A1 (es) Derivados de n-(2-amino-fenil)-amida como inhibidores de hdac
MX2009012885A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene, como sustituyente, grupo fenilo que tiene estructura de ester de acido sulfonico o estructura de amida de acido sulfonico introducida en este, y tiene actividad de enlace al receptor de gluco
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
PE20081882A1 (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa
MY160424A (en) Substituted pyrrolidine-2-carboxyamides.
PE20080906A1 (es) Derivados heteroarilo como inhibidores de citocina
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
PE20061353A1 (es) Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa
PE20141681A1 (es) Inhibidores de btk
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
NO20082388L (no) Heteroaryl substituerte piperidinderivater som L-CPT1 inhibitorer
JO2962B1 (en) Aminopronic derivatives substituted as niprilicin inhibitors
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
PE20071061A1 (es) Derivados de carbonilo como inhibidores de peptidil-deformilasa (pdf)
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
UY30310A1 (es) Derivados 2-azetidinona, sales, solvatos, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
PE20150194A1 (es) Novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa
PE20090620A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed